Delivery Order SPE2DB20D3104-SPE2DB22FV4G5
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The award is for the delivery of VEKLURY 100 mg vials, a pharmaceutical product, to support military treatment programs and facilities. The contract is a firm fixed price delivery order with a ceiling value of $1,361.84 and a period of performance through May 2, 2024. Amerisourcebergen Drug Corp holds an Indefinite...
- This federal contract award, valued at $1,584.88, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VEKLURY 100 MG VIALS, a pharmaceutical product, with a period of performance through April 3, 2025. This award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of VEKLURY 100 MG VIALS. The $13,606.80 firm fixed-price contract has an ultimate completion date of October 21, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of VEKLURY 100 MG VIALS. The award is a Firm Fixed Price Delivery Order with a ceiling value of $15,848.80 and a period of performance ending on July 1, 2025. The contract is not set aside for any specific business category. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide VEKLURY 100 MG VIALS. The $10,213.80 contract has a completion date of February 29, 2024 and does not utilize a set-aside designation. Amerisourcebergen Drug Corp serves as the prime contractor for this award, which is part of a larger indefinite delivery contract with DLA valued up to $999,999,999.00 through...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a firm fixed-price delivery order valued at $6,809.20. The contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the supply of VEKLURY 100 MG VIALS, a critical pharmaceutical product. The contract has an ultimate completion date of August 13, 2024. Amerisourcebergen holds several Indefinite Delivery Contracts (IDCs) with federal agencies, including a $999,999,999 IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution company. The $13,618.40 firm fixed price delivery order is for the supply of VEKLURY 100 MG VIALS, a pharmaceutical product, with a completion date of March 22, 2024. This award is not associated with any set-aside designation. Amerisourcebergen Drug Corp also...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The $20,427.60 firm fixed-price delivery order is for the supply of VEKLURY 100 mg vials, a pharmaceutical product used to treat COVID-19. The contract has an ultimate completion date of August 2, 2024 and does not utilize a set-aside designation. Amerisourcebergen Drug Corp, a subsidiary of the major pharmaceutical distribution company...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of VEKLURY 100 MG VIALS, a pharmaceutical product. The contract is not set aside and has a firm fixed price with a ceiling value of $3,962.10. The contract has an ultimate completion date of June 25, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,320.62 firm fixed-price delivery order is for the supply of VEKLURY 100 MG VIALS, a critical medication. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB22FV4G5Delivery Order
This federal contract award is for the delivery of VEKLURY 100 MG VIAL pharmaceutical products to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $13,606.80 and an ultimate completion date of January 31, 2022. It is a Firm Fixed Price Delivery Order contract, with no set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024 for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.6k | 1/7/22 |